Before revision: A New Drug Application for another exon-skipping Morpholino, golodirsen (targeting dystrophin exon 53), has been accepted by the US FDA and an FDA decision on drug approval is due in August of 2019.
After revision: A New Drug Application for another exon-skipping Morpholino, golodirsen (targeting dystrophin exon 53), was approved in the United States in December 2019.